Listing 14.02 in 2026: How Social Security Decides Systemic Lupus Erythematosus Claims Under 14.02A and 14.02B, Why the Two Body Systems Test and the Repeated Manifestations Path Decide Most Cases, and What Wins When the Listing Falls Short
Systemic lupus erythematosus is one of the trickiest conditions to win on at Social Security. The disease is a chameleon. It looks different from one patient to the next, the symptoms come and go, and the blood work doesn't always track the clinical picture. SSA's response to that complexity is Listing 14.02, which gives two paths to disability under Section 14.00 immune system disorders. Both paths are workable, but each requires a specific evidentiary build that most rheumatologists don't produce by default.
This is the deep dive. We'll walk through Listing 14.02's two routes, what counts as involvement of two or more organs or body systems under 14.02A, what the repeated manifestations path under 14.02B actually demands, how the marked limitation in functioning rule applies, and what to do when the listing isn't met but the disease is still preventing work. We'll also cover overlap syndromes, drug-induced lupus, and a worked example of a real claim path.
SLE claim denied or about to file? A quick screen will tell you whether your case meets 14.02A, 14.02B, or sits in residual functional capacity territory.
See If You QualifyWhere Listing 14.02 sits in the rules
Listing 14.02 lives in Section 14.00 of the adult Listing of Impairments, codified at 20 CFR Part 404, Subpart P, Appendix 1. Section 14.00 covers immune system disorders generally, including connective tissue diseases like SLE, scleroderma, polymyositis, dermatomyositis, mixed connective tissue disease, Sjogren's syndrome, and inflammatory arthritis. Listing 14.02 is the SLE-specific listing.
The 14.00D1 preamble defines SLE for SSA purposes. The agency uses the American College of Rheumatology classification criteria as a reference, although the 2019 ACR/EULAR criteria with an entry requirement of ANA at a titer of at least 1:80 plus weighted clinical and immunologic domains is now the clinical standard. For SSA documentation, the diagnosis has to be supported by the medical record. ANA positive, anti-double-stranded DNA, anti-Smith antibody, anti-Ro, anti-La, low complement, biopsy findings, and clinical features all count as supporting evidence.
The listing has two paths, A and B. You only need to meet one.
The 14.02A path: two organs or body systems with constitutional symptoms
Listing 14.02A grants disability when the patient has involvement of two or more organs or body systems, with one of the organs or body systems involved to at least a moderate level of severity, and at least two of the following constitutional symptoms or signs: severe fatigue, fever, malaise, or involuntary weight loss.
The two-organ test is the heart of 14.02A. SSA expects documented involvement of multiple organ systems. Examples that show up in real lupus files:
- Lupus nephritis. Biopsy-proven Class II through VI by ISN/RPS classification. Class III, IV, or V is generally considered at least moderate. Urinalysis with proteinuria, hematuria, or cellular casts supports the renal involvement.
- Hematologic involvement. Autoimmune hemolytic anemia, leukopenia under 4,000, lymphopenia under 1,500, or thrombocytopenia under 100,000. Persistent or recurrent cytopenias are stronger evidence than transient drops.
- Cardiac involvement. Pericarditis, myocarditis, Libman-Sacks endocarditis, accelerated atherosclerosis. Echocardiogram findings and cardiac MRI carry weight.
- Pulmonary involvement. Pleuritis, pleural effusion, interstitial lung disease, pulmonary hypertension. High-resolution CT and pulmonary function tests document the severity.
- Central nervous system involvement. Cognitive dysfunction, seizures, psychosis, transverse myelitis, cerebrovascular disease, peripheral neuropathy. Neuroimaging and neuropsychological testing support the CNS findings.
- Musculoskeletal involvement. Inflammatory polyarthritis, often non-erosive. Synovitis on exam, joint swelling, morning stiffness.
- Skin involvement. Discoid lesions, malar rash, photosensitivity, oral ulcers, alopecia. Biopsy can confirm cutaneous lupus.
- Vascular involvement. Raynaud's phenomenon, antiphospholipid syndrome with thrombotic events, vasculitis.
To meet 14.02A, at least one of the involved systems has to be at moderate level. The 14.00C1 preamble defines moderate severity as the level at which the impairment significantly limits the claimant's ability to function. Mild proteinuria with normal kidney function probably doesn't reach moderate. Biopsy-proven Class IV lupus nephritis with serum creatinine of 1.6 reaches moderate easily.
Then you need at least two of the four constitutional symptoms: severe fatigue, fever, malaise, or involuntary weight loss. Severe fatigue means a "frequent sense of exhaustion that results in significantly reduced physical activity or mental function." This is the SSA definition at 14.00C2. Treating rheumatology notes should document the fatigue specifically, not just mention "tired." Weight loss should be quantified with baseline and current weights.
The 14.02B path: repeated manifestations with marked limitation
Listing 14.02B grants disability when the patient has repeated manifestations of SLE, with at least two of the constitutional symptoms or signs (severe fatigue, fever, malaise, involuntary weight loss), and one of the following at the marked level:
- Limitation of activities of daily living.
- Limitation in maintaining social functioning.
- Limitation in completing tasks in a timely manner due to deficiencies in concentration, persistence, or pace.
The 14.02B path is the lupus-specific application of the broader Section 14.00 framework. Repeated manifestations means the same lupus features recurring over time or different features appearing in succession. A patient who flares three or four times a year with overlapping symptoms (arthritis, rash, fatigue, cytopenias) is the textbook 14.02B candidate.
The marked level rating is critical. 14.00I3 defines marked as more than moderate but less than extreme. It limits the claimant's ability to function independently, appropriately, effectively, and on a sustained basis. The functional rating has to come from the medical record and the medical source statement, not just the claimant's self-report.
Activities of daily living covers cooking, cleaning, shopping, banking, household chores, hobbies, personal care, and similar activities. Marked limitation in ADLs typically means the claimant can do some of these activities but cannot sustain them at a normal pace or frequency without significant breaks.
Social functioning covers the ability to interact appropriately with family, friends, neighbors, and others. SLE patients often develop social withdrawal due to fatigue, cognitive symptoms, depression, and the unpredictability of flares. Marked limitation in social functioning shows up as inability to maintain friendships, conflicts with family, inability to deal with the public, and isolation.
Concentration, persistence, or pace covers the ability to sustain focused mental work activity. Lupus fog (cognitive dysfunction from SLE) is well documented in the rheumatology literature. Patients describe difficulty with word finding, short-term memory, multitasking, and sustained attention. Neuropsychological testing can document objective cognitive impairment.
Constitutional symptoms: the gatekeeper
Both 14.02A and 14.02B require at least two of the four constitutional symptoms or signs. This is the SSA gatekeeper for SLE listings. Without two of the four, neither path works.
The four constitutional symptoms or signs under 14.00C2:
- Severe fatigue. Frequent exhaustion resulting in significantly reduced physical activity or mental function.
- Fever. Documented elevation of temperature, often persistent or recurrent.
- Malaise. Frequent feelings of illness, bodily discomfort, or lack of well-being that result in significantly reduced physical activity or mental function.
- Involuntary weight loss. Documented decline in weight from baseline.
Treating rheumatology notes should document at least two of these specifically. The notes should not just say "fatigue present" but should describe what the fatigue prevents the patient from doing, how long it lasts, and how it interacts with activity. The 14.00C2 standard is "frequent" and "significantly reduced." That language has to show up in the record.
Treatment record and immunosuppressant history
The 2026 SLE treatment record is more complex than it was a decade ago. Standard of care includes hydroxychloroquine (Plaquenil) for all SLE patients, glucocorticoids for flares, immunosuppressants like methotrexate, azathioprine, and mycophenolate mofetil (CellCept), and biologics like belimumab (Benlysta) for active disease. Anifrolumab (Saphnelo) is approved for moderate to severe SLE with type I interferon signature. Voclosporin (Lupkynis) is approved for active lupus nephritis. Rituximab is used off-label for refractory disease.
SSA wants the treatment history documented in the file. Hydroxychloroquine alone with stable disease usually doesn't meet a listing. A patient on hydroxychloroquine plus mycophenolate plus belimumab who is still flaring has refractory disease that supports the severity finding. A patient who has cycled through three or four immunosuppressants because of side effects (azathioprine intolerance, methotrexate hepatotoxicity, mycophenolate GI issues) has a different but equally severe profile.
Glucocorticoid dependence is its own story. Patients on long-term prednisone (more than 7.5 mg daily for over a year) develop osteoporosis, cataracts, hyperglycemia, weight gain, mood changes, and adrenal suppression. The steroid side effects can themselves support residual limitations if the listing isn't met directly.
When the listing isn't met: residual functional capacity
Many SLE claims don't meet 14.02A or 14.02B. The patient has SLE, has constitutional symptoms, but the two-organ test or the marked functional limitation isn't fully satisfied. These cases move to Steps 4 and 5 through residual functional capacity.
The SLE residual case rests on specific functional limitations:
- Fatigue and absenteeism. Flares cause days of complete incapacity. Documented flare frequency translates directly to expected absences per month. Vocational experts testify that more than 1 to 2 absences per month rules out competitive employment.
- Cognitive dysfunction. Lupus fog limits concentration, persistence, and pace. Neuropsychological testing can document objective impairment.
- Joint involvement. Inflammatory polyarthritis limits sitting, standing, lifting, and fine motor tasks. Synovitis on exam supports the limitation.
- Raynaud's and cold intolerance. Many SLE patients can't work in cold environments and have functional limits during temperature transitions.
- Photosensitivity. UV exposure triggers flares. Work environments with significant UV (outdoor jobs, fluorescent lighting in some cases) are problematic.
- Medication side effects. Steroid side effects, immunosuppressant infection risk, biologic infusion schedules all add functional limits.
The medical source statement from the treating rheumatologist is the central evidence. It should translate disease activity and symptoms into specific work limits: maximum sitting time, lifting capacity, off-task percentage, expected monthly absences, environmental restrictions, and cognitive function ratings.
The worked example
Claimant profile. 38-year-old female legal secretary. Diagnosed with SLE in 2019. Initial presentation: malar rash, photosensitivity, oral ulcers, inflammatory polyarthritis, fatigue. ANA positive 1:1280 speckled, anti-dsDNA positive, anti-Smith positive, low C3 and C4, leukopenia. Renal biopsy 2021 showed Class IV lupus nephritis. Treatment: hydroxychloroquine, mycophenolate mofetil 2 grams daily, prednisone tapered between 5 and 20 mg, belimumab IV monthly since 2022, anifrolumab added 2024. Persistent disease activity with periodic flares.
14.02A analysis. Two or more organs or body systems involved: renal (biopsy-proven Class IV lupus nephritis), hematologic (persistent leukopenia under 4,000), musculoskeletal (inflammatory polyarthritis), and cutaneous (active malar rash and photosensitivity). At least one system at moderate severity: Class IV lupus nephritis with proteinuria 1.8 g/24h and serum creatinine 1.3 meets the moderate threshold.
Constitutional symptoms. Severe fatigue documented in every rheumatology note, including specific descriptions of inability to sustain household activities for more than 1 to 2 hours. Involuntary weight loss of 14 percent from baseline over 18 months. Two of the four constitutional symptoms present.
What wins. The case meets 14.02A at Step 3. Two organ systems involved (renal at moderate severity, hematologic, musculoskeletal, cutaneous), plus severe fatigue and weight loss. Approval at the DDS level with established onset date matching the 2021 lupus nephritis diagnosis. SSDI back pay covers 12 months prior to application.
14.02B backup. Even if 14.02A were marginal, 14.02B would apply. Repeated manifestations across multiple body systems, two constitutional symptoms, and marked limitation in ADLs (treating rheumatologist documented inability to sustain household chores, cooking, or grocery shopping without rest breaks of 1 to 2 hours).
Overlap syndromes and related conditions
SLE often overlaps with other autoimmune diseases. Mixed connective tissue disease (Sharp syndrome) involves features of SLE, scleroderma, and polymyositis with anti-U1-RNP antibodies. Sjogren's syndrome with secondary SLE is common. Antiphospholipid syndrome (APS) frequently coexists with SLE and carries its own thrombotic and pregnancy-related complications.
SSA evaluates overlap syndromes by applying the most relevant listing or by combining listings under 20 CFR 404.1526 medical equivalence. A patient with SLE plus APS plus Sjogren's might not meet any single listing but could medically equal one based on the combined severity. The treating rheumatologist's documentation should describe the overlap pattern explicitly.
Drug-induced lupus deserves separate handling. Hydralazine, procainamide, isoniazid, minocycline, and certain biologics can produce a lupus-like syndrome with positive ANA and anti-histone antibodies. Drug-induced lupus usually resolves after discontinuation of the offending drug and rarely meets the Listing 14.02 criteria because it's transient. SSA adjudicators are trained to look for this pattern and may deny based on the expected resolution.
State-by-state notes
SLE claims are processed at the state DDS level. Allowance rates at initial determination vary widely. Some states have specialty medical consultants who handle rheumatology cases. If your state has a backlog and your file is strong, consider whether your case is appropriate for an on-the-record decision request at the ALJ level. See state-specific guides for California, Texas, Florida, New York, and Georgia.
Related deep dives
- Listing 14.09 inflammatory arthritis deep dive
- Social Security Disability for lupus overview
- Listing 6.03 to 6.05 chronic kidney disease deep dive
- Medical equivalence under 20 CFR 404.1526
- SSR 16-3p subjective symptom evaluation
Trying to figure out whether your lupus claim meets 14.02A or 14.02B? A two-minute screen will give you a clear answer.
See If You QualifyFrequently asked questions
Does positive ANA alone qualify for SSDI under Listing 14.02?
No. Positive ANA is common in the general population and doesn't establish SLE on its own. Listing 14.02 requires a documented diagnosis of SLE supported by the clinical and immunologic findings outlined in 14.00D1, plus either the 14.02A two-organ pattern with constitutional symptoms or the 14.02B repeated manifestations with marked functional limitation.
What counts as moderate severity in one of the organ systems under 14.02A?
14.00C1 defines moderate as a level that significantly limits the claimant's ability to function. Examples include biopsy-proven Class III, IV, or V lupus nephritis, persistent cytopenias that affect daily function, active pericarditis requiring colchicine or steroids, interstitial lung disease with reduced DLCO, or CNS lupus with cognitive impairment confirmed on neuropsych testing. The threshold isn't a specific lab number. It's the functional impact of the organ involvement.
How do I document severe fatigue under the constitutional symptoms requirement?
Treating rheumatology notes should specifically describe the fatigue as causing significantly reduced physical activity or mental function. Generic mentions of "tired" or "fatigued" are weak. Strong documentation describes what the fatigue prevents you from doing, how long episodes last, how many days per week, and how the fatigue responds (or doesn't) to rest. Patient-completed fatigue scales like the Fatigue Severity Scale or the FACIT-F can add objective measurement.
Does cognitive dysfunction (lupus fog) help my claim?
Yes, particularly under 14.02B as marked limitation in completing tasks due to deficiencies in concentration, persistence, or pace. Neuropsychological testing documenting objective impairment is the strongest evidence. The treating rheumatologist or neurologist can also document observed cognitive symptoms in office visits. SSA also evaluates CNS lupus under Section 12.00 mental impairment listings when the cognitive symptoms are severe enough.
What if I'm on belimumab or anifrolumab and the disease is mostly controlled?
Treatment that controls disease without eliminating symptoms can still support a listing or residual case. Document what the treatment does and doesn't fix. If belimumab reduces flares but you still have fatigue, joint pain, and cognitive dysfunction, those persistent symptoms can support 14.02B with marked limitation. If anifrolumab brought you into remission and you have no current symptoms, the listing probably isn't met and the case becomes about functional capacity with the residual disease activity.
How do antiphospholipid syndrome and thrombotic events affect my SLE claim?
APS frequently coexists with SLE and adds independent disability risk. A history of pulmonary embolism, deep vein thrombosis, stroke, or recurrent pregnancy loss adds significant weight to the claim. APS is evaluated under Section 14.00 immune system disorders. Thrombotic events with residual neurologic deficits get evaluated under Section 11.00 neurological listings. Combined SLE plus APS often supports medical equivalence to a listing under 20 CFR 404.1526.
Will steroid side effects support my claim if the lupus is partially controlled?
Yes. Long-term prednisone produces osteoporosis, vertebral compression fractures, cataracts, glaucoma, hyperglycemia and steroid-induced diabetes, weight gain, hypertension, mood changes, and adrenal suppression. Each of these can support residual functional limitations. A patient who has been on prednisone for years often has multiple comorbid conditions that combine with the underlying SLE to exceed listing-level severity.